1921
Volume 73, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Selective immunization of at-risk groups may reduce the incidence of hepatitis A infection, but only the inclusion of hepatitis A vaccine in a routine universal childhood immunization schedule would guarantee control of the infection. But the interference by maternally derived hepatitis A antibodies (anti-HAV) with the immunogenicity of inactivated hepatitis A vaccine is still important in the determination of the optimal age for hepatitis A vaccination. The hepatitis A vaccines have not been assessed widely in children under the age of 2 years and are not currently licensed for this age group in many countries. A prospective trial was performed to detect seroprevalence of maternal hepatitis A antibodies during the first 2 years of life among young infants born to hepatitis A antibody positive mothers in Turkey. We measured at-birth anti-HAV in 147 infants born in our hospital and in their mothers and then from the offspring at months 3, 6, 9, 12, 15, 18, 21, and 24. The prevalence of seropositivity among the mothers at birth were found similarly high (93.9%) to the studies previously done among the adults in our area. The prevalence of anti-HAV among children aged 0, 9, 12, 15, 18, and 21 months were 93.9%, 62.6%, 36.1%, 13.6%, 6.1%, and 0.7%, respectively. Although a proportion of infants still had measurable antibodies at 9 and 12 month of age, two thirds of the infants over the age of 12 months were at high risk of acquiring hepatitis A infection, as living in a endemic region.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2005.73.457
2005-08-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/73/2/0730457.html?itemId=/content/journals/10.4269/ajtmh.2005.73.457&mimeType=html&fmt=ahah

References

  1. Hadler SC, Webster HM, Erben JJ, Swanson JE, Mayhard JE, 1980. Hepatitis A in day care centers: a communitywide assessment. N Engl J Med 302 : 1222–1227.
  2. Centers For Diseases Control and Prevention, Hepatitis Surveillance Report No.57. Atlanta: Centers for Disease Control and Prevention, 2000.
  3. Aranklle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, 1995. Age specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 171 : 447–450.
  4. Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA, 1999. Exposure of Indian children to hepatitis A virus and vaccination age. Indian J Med Res 109 : 11–15.
  5. Smith PF, Grabau JC, Werzberger A, Gunn RA, Rolka HR, Kondracki SF, Gallo RS, Morse DL, 1997. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 118 : 243–252.
  6. Shapiro CN, Letson GW, Kuehn D, 1995. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants (Abstract H-16). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, September 17–20, 1995). Washington, DC: American Society for Microbiology, 190.
  7. Siegrist CA, Cordova M, Brandt C, Barrios C, Berney M, Tougne C, Kovarik J, Lambert PH, 1998. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine 16 : 1409–1414.
  8. Lieberman JM, Chang S, Partridge S, Hollister JG, Kaplan KM, Jensen EH, Kater B, Ward JI, 2002. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 21 : 347–348.
  9. De Silvestri A, Avanzini MA, Terulla V, Zucca S, Polatti I, Belloni C, 2002. Decline of maternal hepatitis A virus antibody levels in infants. Acta Paedtr 91 : 882–884.
  10. Horng Y, Chang M, Lee C, Safary A, Andre FE, Chen DS, 1993. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 12 : 359–362.
  11. Committee on Infectious Diseases Recommended Childhood Immunization Schedule United States, 2001. January–December 2001. Pediatrics 107 : 202–204.
  12. Kanra G, Yalçin SS, Ceyhan M, Yurdakok K, 2000. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month old children. Turk J Pediatr 42 : 105–108.
  13. Piazza M, Safary A, Vegnente A, Soncini R, Pensati P, Sardo M, Orlando R, Tosone G, Picciotto L, 1999. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination program. Vaccine 17 : 585–588.
  14. Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S, 2000. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 : 1045–1055.
  15. Kanra G, Yalçin SS, Kara A, Ozmert E, Yurdakok K, 2002. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J. 21 : 727–730.
  16. Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, Culver D, Bell BP, Margolis HS, 2003. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 22 : 354–359.
  17. Linder N, Karetnyl Y, Gidony Y, Dagan R, Ohel G, Levin E, Mendelson E, Barzilai A, 1999. Decline of hepatitis A antibodies during the first 7 months of life in full term and preterm infants. Infection 27 : 128–131.
  18. Yapicioglu H, Alhan E, Yildizdas D, Yaman A, Bozdemir N, 2002. Prevalence of hepatitis A in children and adolescents in Adana, Turkey. Indian Pediatrics 39 : 936–941.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2005.73.457
Loading
/content/journals/10.4269/ajtmh.2005.73.457
Loading

Data & Media loading...

  • Received : 31 Oct 2004
  • Accepted : 22 Jan 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error